SCHEMBL1021273

SCHEMBL1021273

O=C1C=CC=C2C=CCN=C12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19423555 0.98
SCHEMBL987744 0.71
SCHEMBL29103257 0.70
SCHEMBL2357161 0.68
SCHEMBL19695101 0.64
SCHEMBL4815330 0.63
SCHEMBL2363962 0.61
SCHEMBL9820299 0.60
SCHEMBL28789855 0.60
SCHEMBL2051934 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608401-A2 MK2 INHIBITORS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-09-03 EP claimed
US-20240190890-A1 MK2 INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2024-06-13 US claimed
WO-2024092115-A2 MK2 INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-05-02 WO claimed
CN-117460264-A Perovskite solar cell and preparation method thereof 上海乐天钙钛光电科技有限公司 2024-01-26 CN claimed
EP-1368357-A1 TRICYCLIC QUINOLINONE AND TRICYCLIC QUINOLINE AS ANDROGEN RECEPTOR MODULATOR COMPOUNDS LIGAND PHARMACEUTICALS INCORPORATED (US) 2003-12-10 EP claimed
WO-2002068427-A1 TRICYCLIC QUINOLINONE AND TRICYCLIC QUINOLINE AS ANDROGEN RECEPTOR MODULATOR COMPOUNDS LIGAND PHARMACEUTICALS INCORPORATED (US) 2002-09-06 WO claimed
CN-122028714-A Method for manufacturing semiconductor device and composition for coating patterned photoresist 台湾积体电路制造股份有限公司 2026-05-12 CN disclosed
US-20260109708-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE CELGENE CORP (US) 2026-04-23 US disclosed
EP-4661875-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE Celgene Corporation (US) 2025-12-17 EP disclosed
EP-4608401-A2 MK2 INHIBITORS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-09-03 EP disclosed
CN-119998423-A Dial agent 大金工业株式会社 2025-05-13 CN disclosed
CN-116137841-B Coloring dispersion for inkjet, ink for inkjet recording, and inkjet recording method 日本化药株式会社 2025-04-25 CN disclosed
CN-119895010-A Dial agent 大金工业株式会社 2025-04-25 CN disclosed
EP-0061688-B1 PROCESS FOR THE CONTROLLED MICROBIAL DEGRADATION OF BILE ACIDS Henkel Kommanditgesellschaft auf Aktien (DE) 1985-08-28 EP disclosed
US-4362815-A DEGRADATION OF STEROIDS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1982-12-07 US disclosed
EP-0061688-A1 Process for the controlled microbial degradation of bile acids Henkel Kommanditgesellschaft auf Aktien (DE) 1982-10-06 EP disclosed
EP-0015308-A1 Process for the selective degradation of side chains of steroid compounds and for the preparation of the appropriate defective microorganism mutants and microorganism strains Henkel Kommanditgesellschaft auf Aktien (DE) 1980-09-17 EP disclosed
EP-0005505-A2 Open-cell foamed polyurethane resins containing compounds forming chelates and/or complexes of chelates, process for their preparation and their application to the adsorption of heavy-metal ions from waste water BASF Aktiengesellschaft (DE) 1979-11-28 EP disclosed
US-4152161-A Photographic silver halide emulsion with hetero-N containing polymeric binder AGFA-GEVAERT, A.G. (DE) 1979-05-01 US disclosed
US-3960762-A Production of absorbents BAYER AKTIENGESELLSCHAFT (DT) 1976-06-01 US disclosed